-
Pat Flood (@rebarcock) passed away 9/21/25. Pat played a huge role in encouraging the devolopmemt of this site and donated the very first dollar to get it started. Check the thread at the top of the board for the obituary and please feel free to pay your respects there. I am going to get all the content from that thread over to his family so they can see how many people really cared for Pat outside of what they ever knew. Pat loved to tell stories and always wanted everyone else to tell stories. I think a great way we can honor Pat is to tell a story in his thread (also pinned at the top of the board).
Master Thread Dance Your Cares Away/Fraggle/Law Abiding Citizens
- Thread starter Bryan74b
- Start date
Master Threads
ShaolinNole
Legendary
Removed license tags. You can make napalm with gasoline and detergent. Something fucky’s gonna happen.
****Rittenhouse FAFO CHAMP 2021****
Maybe they're a shelter and going to do all the homeless folks' laundry? That's a lot a damn detergent.
I remember the days when looters were shot on sight. I miss those days alot.
Liberalism at it's best.
BLM leader threatens ‘riots, fire, bloodshed’ in NYC if Eric Adams gets tough on crime
A Black Lives Matter leader said there will be “bloodshed” after debating police reform with Eric Adams during a sit-down with the Democrat at Brooklyn Borough Hall.
nypost.com
Mentioned this quite a few times. I intentionally ignored politics my entire life until the Kavanaugh BS. As the tweet claims - that was my red pill moment. Obviously no where near alone.
Rittenhouse should be just as powerful if it plays out honestly. More and more will start paying attention after being lied to over and over again. Once you see the gas lighting propoganda, you can't unsee it.
No way the majority of this country has lost our collective minds. More and more sheeple like myself need the damn pill ASAP. The end game to the "great awakening" needs to be to take our country back from the political elite - regardless of party affiliation.
You can't count the practice targets that they've constructed lately. Our people in charge need to worry about training officers that don't run into underwater mountains with billion dollar submarines.
BLM leader threatens ‘riots, fire, bloodshed’ in NYC if Eric Adams gets tough on crime
A Black Lives Matter leader said there will be “bloodshed” after debating police reform with Eric Adams during a sit-down with the Democrat at Brooklyn Borough Hall.
Will be interesting to watch this social experiment unfold. I may be wrong but I've yet to see anyone with BLM actually take ownership and responsibility for anything.
I hope so
Cautionary note, I presume more and more Russians awoke to the realities of a bolshevik led world and that did nothing to stop them
We must continue to seek, find, express the truth and not comply with the obvious lies
If enough of us do that, that's the plan
Well she did acknowledge that she purchased a couple of million $$ homes.
She is either willfully ignorant of her surroundings (the woman was kicked out of a leadership position within her very own party for crying put loud) or all of this is intentional on her part to try and make a little bank on her way out of politics, because she will not ever be elected with an R next to her name again. Would she poll higher than K. Harris did? LOL. She has proven to be just like every other RINO out there. She is basically the perfect candidate for the Lincoln Project to support. Which should be enough to know she is toxic and not someone anyone should vote for.For a good laugh this evening
Liz Cheney Sparks Further Speculation She's Running in 2024 As She Rails Against Trump in NH Speech
It made for a good laugh a few months ago when Rep. Liz Cheney (R-WY), a particularly fierce critic of former President Donald Trump, indicated she wasn't ruling out atownhall.com
Her lack of support for Trump is one thing, but when she starts talking about peaceful transfers of power and did nothing to hold the Obama administration from the same standard, you lose your voice IMO.
LeBron James ripped for mocking Kyle Rittenhouse’s breakdown in court
LeBron James posted a series of laughing emojis alongside footage of the 18-year-old Kenosha gunman overwhelmed by sobs Wednesday, a breakdown that forced a halt to his trial.
nypost.com
Lawyer for ‘Rust’ armorer Hannah Gutierrez-Reed claims she was ‘framed’
“Rust” armorer Hannah Gutierrez-Reed’s attorney said that his client is being “framed” for the tragic death that occurred when Alec Baldwin shot the film’s cinem…
nypost.com
Dad gets 28 years for leaving toddler to die in burning car after police chase
A South Carolina man who left his 19-month-old daughter to die in a burning car after a police chase has been hit with a 28-year prison sentence in the horrific crime.
nypost.com
BTAvenger
Elite
I literally have no idea anymore how to decipher what shit is real and what is parody.
End the Fed. Cut out the money tree and put an end to the corporate and private pillaging of America.
I have no problem paying taxes, but there’s no reason to be taxed every time we touch our wallets.
Ballooned contracts made with underperforming materials, all for the kicks backs and election financing.
Sending money overseas to launder it back too their cronies bank accounts. All the while wanting to check our bank accounts to make sure they don’t get “robbed” a single cent of our money.
I’m over it. I’m over the lies and constant brainwashing. I’m over 17 year old kids sitting in jail for months for obvious self defense. I’m over false narratives designed to make our countrymen look as bad as possible in an effort to justify this socialist bullshit.
They’ve created an army of idiots, with their corporate bullhorn, that’s effectively shielded their terrible morals and ethics from the public’s wrath.
I love this dirt. It’s created the greatest and most dangerous country in world history.
If enough good men and women awaken, and If enough understand that this threat will never go away. We can win.
Freedom isn’t won. It’s maintained.
Pineapple
Legendary
Can he play QB?
Just another example that proof-reading should be a college major field.
Good luck to her.
Isn't this prima facie evidence of the deleterious effects these Jabs have on lungs either near term or sometime in the future?
Just like Italy drastically reducing the number of Wuhan deaths, how many false positives have resulted in all the bullshit we're forced to endure?
FDA recalling 2 million Ellume at-home COVID-19 test kits because of false positives
The federal regulatory agency says the recall stems from a manufacturing defect found in some 2 million tests.www.npr.org
Can You Google What You Might Need - Amazing the Info Out There - Maybe a Start
Contact a PI?
Use Your MIL Network I'm Sure You Know Someone That Knows The Right Person
Now - More DEETS Please!
FIFY
What do we have here....
www.nytimes.com
Pfizer’s tactics included delaying the publication of studies that had found no evidence the drug worked for some other disorders, “spinning” negative data to place it in a more positive light, and bundling negative findings with positive studies to neutralize the results, according to written reports by the experts, who analyzed the documents at the request of the plaintiffs’ lawyers.
One of the experts who reviewed the documents, Dr. Kay Dickersin of the Johns Hopkins Bloomberg School of Public Health, concluded that the Pfizer documents spell out “a publication strategy meant to convince physicians of Neurontin’s effectiveness and misrepresent or suppress negative findings.”
Pfizer issued a statement Tuesday denying that it had manipulated Neurontin data, saying “study results are reported by Pfizer in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations of the study, and are reported regardless of the outcome of the study or the country in which the study was conducted.”
The expert reports, unsealed Monday in a federal court in Boston, add to accusations that the pharmaceutical industry has controlled the flow of clinical research data, blurring the lines between science and marketing.
In April, for example, a group of academic doctors questioned the validity of drug industry research after finding that Merck had hired ghostwriters to produce scientific articles about Vioxx, then recruited prestigious doctors to serve as their official authors. Vioxx, a painkiller, was withdrawn from the market in 2004 after research indicated it could cause strokes and heart attacks.
Last winter, Merck and Schering-Plough were criticized for delaying the release of a study on their best-selling cholesterol medication Vytorin that showed the drug did not slow the growth of plaque in arteries. In the case of Pfizer’s Neurontin, the negative studies would have increased doubts about the drug’s value for several unapproved uses treating bipolar disorder, controlling certain types of pain and preventing migraine headaches, according to the expert opinions.
So-called off-label use of Neurontin for those conditions helped propel its sales to nearly $3 billion a year before it lost patent protection in 2004.
In one example, the experts concluded that Pfizer had deliberately delayed release of a study that showed the drug had little effect against pain that is a complication of long-term diabetes, even as the outside researcher who was a lead investigator for the study, Dr. John Reckless of Bath, England, pushed to publish the unflattering findings on his own. Dr. Reckless’s office said Tuesday that he could not be reached for comment.
According to one September 2000 e-mail message by a Neurontin team leader at Pfizer, “The main investigator in the U.K. (Dr. Reckless) is keen to publish but this will have several ramifications.” The team leader later wrote, “I think we can limit the potential downside of the 224 study by delaying publication for as long as possible.”
Pfizer said Tuesday that it had submitted the Reckless study to two journals which declined to publish it. The results were not published until 2003 and, according to plaintiffs’ experts, when they did appear they were combined with two other studies and together the findings concluded Neurontin was effective for treating neuropathic pain.
Another series of e-mail messages had the subject line “Spinning Serpell,” a reference to an investigator on the study, Dr. Michael Serpell of Glasgow, Scotland. In the e-mail exchange a senior marketing manager for Pfizer and a professional medical writer discussed how to cast the results in a more favorable light for a poster presentation at a medical conference, the experts concluded.
“If Pfizer wants to use, present and publish this comparative data analysis in which two of the five studies compared make the overall picture look bad, how do we make it sound better than it looks on the graphs?” the medical writer asked.
Pfizer discontinued its marketing program for Neurontin in 2004 after the drug became available as a generic. That same year, the company paid $430 million to settle federal criminal and civil claims that Warner-Lambert, which Pfizer acquired in 2000, promoted Neurontin for unapproved uses during the 1990s.
At the time, Pfizer said the illegal marketing had occurred before Pfizer acquired the company or drug. On Tuesday, Pfizer repeated that it had instituted procedures when it acquired Warner-Lambert to make sure there was no off-label promotion of Neurontin.
Despite that settlement, separate legal action involving the drug is still pending in Boston, where consumers and third-party payers including insurance companies and trade unions want Pfizer to repay them billions of dollars for Neurontin prescriptions. The plaintiffs accuse Pfizer of fraudulently misrepresenting the drug’s benefits.
Experts Conclude Pfizer Manipulated Studies (Published 2008)
The drug maker manipulated the publication of studies to bolster use of its epilepsy drug Neurontin, according to expert witnesses in a lawsuit against the company.
Experts Conclude Pfizer Manipulated Studies
The drug maker Pfizer earlier this decade manipulated the publication of scientific studies to bolster the use of its epilepsy drug Neurontin for other disorders, while suppressing research that did not support those uses, according to experts who reviewed thousands of company documents for plaintiffs in a lawsuit against the company.Pfizer’s tactics included delaying the publication of studies that had found no evidence the drug worked for some other disorders, “spinning” negative data to place it in a more positive light, and bundling negative findings with positive studies to neutralize the results, according to written reports by the experts, who analyzed the documents at the request of the plaintiffs’ lawyers.
One of the experts who reviewed the documents, Dr. Kay Dickersin of the Johns Hopkins Bloomberg School of Public Health, concluded that the Pfizer documents spell out “a publication strategy meant to convince physicians of Neurontin’s effectiveness and misrepresent or suppress negative findings.”
Pfizer issued a statement Tuesday denying that it had manipulated Neurontin data, saying “study results are reported by Pfizer in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations of the study, and are reported regardless of the outcome of the study or the country in which the study was conducted.”
The expert reports, unsealed Monday in a federal court in Boston, add to accusations that the pharmaceutical industry has controlled the flow of clinical research data, blurring the lines between science and marketing.
In April, for example, a group of academic doctors questioned the validity of drug industry research after finding that Merck had hired ghostwriters to produce scientific articles about Vioxx, then recruited prestigious doctors to serve as their official authors. Vioxx, a painkiller, was withdrawn from the market in 2004 after research indicated it could cause strokes and heart attacks.
Last winter, Merck and Schering-Plough were criticized for delaying the release of a study on their best-selling cholesterol medication Vytorin that showed the drug did not slow the growth of plaque in arteries. In the case of Pfizer’s Neurontin, the negative studies would have increased doubts about the drug’s value for several unapproved uses treating bipolar disorder, controlling certain types of pain and preventing migraine headaches, according to the expert opinions.
So-called off-label use of Neurontin for those conditions helped propel its sales to nearly $3 billion a year before it lost patent protection in 2004.
In one example, the experts concluded that Pfizer had deliberately delayed release of a study that showed the drug had little effect against pain that is a complication of long-term diabetes, even as the outside researcher who was a lead investigator for the study, Dr. John Reckless of Bath, England, pushed to publish the unflattering findings on his own. Dr. Reckless’s office said Tuesday that he could not be reached for comment.
According to one September 2000 e-mail message by a Neurontin team leader at Pfizer, “The main investigator in the U.K. (Dr. Reckless) is keen to publish but this will have several ramifications.” The team leader later wrote, “I think we can limit the potential downside of the 224 study by delaying publication for as long as possible.”
Pfizer said Tuesday that it had submitted the Reckless study to two journals which declined to publish it. The results were not published until 2003 and, according to plaintiffs’ experts, when they did appear they were combined with two other studies and together the findings concluded Neurontin was effective for treating neuropathic pain.
Another series of e-mail messages had the subject line “Spinning Serpell,” a reference to an investigator on the study, Dr. Michael Serpell of Glasgow, Scotland. In the e-mail exchange a senior marketing manager for Pfizer and a professional medical writer discussed how to cast the results in a more favorable light for a poster presentation at a medical conference, the experts concluded.
“If Pfizer wants to use, present and publish this comparative data analysis in which two of the five studies compared make the overall picture look bad, how do we make it sound better than it looks on the graphs?” the medical writer asked.
Pfizer discontinued its marketing program for Neurontin in 2004 after the drug became available as a generic. That same year, the company paid $430 million to settle federal criminal and civil claims that Warner-Lambert, which Pfizer acquired in 2000, promoted Neurontin for unapproved uses during the 1990s.
At the time, Pfizer said the illegal marketing had occurred before Pfizer acquired the company or drug. On Tuesday, Pfizer repeated that it had instituted procedures when it acquired Warner-Lambert to make sure there was no off-label promotion of Neurontin.
Despite that settlement, separate legal action involving the drug is still pending in Boston, where consumers and third-party payers including insurance companies and trade unions want Pfizer to repay them billions of dollars for Neurontin prescriptions. The plaintiffs accuse Pfizer of fraudulently misrepresenting the drug’s benefits.
BLM leader threatens ‘riots, fire, bloodshed’ in NYC if Eric Adams gets tough on crime
A Black Lives Matter leader said there will be “bloodshed” after debating police reform with Eric Adams during a sit-down with the Democrat at Brooklyn Borough Hall.
Negotiating with terrorists.
Why the Fvck is anyone in a position of power wasting time with those clowns.
Tell those pieces of shit to kick rocks and GTFO!!
Pfizer has plenty of billions to pay in settlements.What do we have here....
Experts Conclude Pfizer Manipulated Studies (Published 2008)
The drug maker manipulated the publication of studies to bolster use of its epilepsy drug Neurontin, according to expert witnesses in a lawsuit against the company.
Experts Conclude Pfizer Manipulated Studies
The drug maker Pfizer earlier this decade manipulated the publication of scientific studies to bolster the use of its epilepsy drug Neurontin for other disorders, while suppressing research that did not support those uses, according to experts who reviewed thousands of company documents for plaintiffs in a lawsuit against the company.
Pfizer’s tactics included delaying the publication of studies that had found no evidence the drug worked for some other disorders, “spinning” negative data to place it in a more positive light, and bundling negative findings with positive studies to neutralize the results, according to written reports by the experts, who analyzed the documents at the request of the plaintiffs’ lawyers.
One of the experts who reviewed the documents, Dr. Kay Dickersin of the Johns Hopkins Bloomberg School of Public Health, concluded that the Pfizer documents spell out “a publication strategy meant to convince physicians of Neurontin’s effectiveness and misrepresent or suppress negative findings.”
Pfizer issued a statement Tuesday denying that it had manipulated Neurontin data, saying “study results are reported by Pfizer in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations of the study, and are reported regardless of the outcome of the study or the country in which the study was conducted.”
The expert reports, unsealed Monday in a federal court in Boston, add to accusations that the pharmaceutical industry has controlled the flow of clinical research data, blurring the lines between science and marketing.
In April, for example, a group of academic doctors questioned the validity of drug industry research after finding that Merck had hired ghostwriters to produce scientific articles about Vioxx, then recruited prestigious doctors to serve as their official authors. Vioxx, a painkiller, was withdrawn from the market in 2004 after research indicated it could cause strokes and heart attacks.
Last winter, Merck and Schering-Plough were criticized for delaying the release of a study on their best-selling cholesterol medication Vytorin that showed the drug did not slow the growth of plaque in arteries. In the case of Pfizer’s Neurontin, the negative studies would have increased doubts about the drug’s value for several unapproved uses treating bipolar disorder, controlling certain types of pain and preventing migraine headaches, according to the expert opinions.
So-called off-label use of Neurontin for those conditions helped propel its sales to nearly $3 billion a year before it lost patent protection in 2004.
In one example, the experts concluded that Pfizer had deliberately delayed release of a study that showed the drug had little effect against pain that is a complication of long-term diabetes, even as the outside researcher who was a lead investigator for the study, Dr. John Reckless of Bath, England, pushed to publish the unflattering findings on his own. Dr. Reckless’s office said Tuesday that he could not be reached for comment.
According to one September 2000 e-mail message by a Neurontin team leader at Pfizer, “The main investigator in the U.K. (Dr. Reckless) is keen to publish but this will have several ramifications.” The team leader later wrote, “I think we can limit the potential downside of the 224 study by delaying publication for as long as possible.”
Pfizer said Tuesday that it had submitted the Reckless study to two journals which declined to publish it. The results were not published until 2003 and, according to plaintiffs’ experts, when they did appear they were combined with two other studies and together the findings concluded Neurontin was effective for treating neuropathic pain.
Another series of e-mail messages had the subject line “Spinning Serpell,” a reference to an investigator on the study, Dr. Michael Serpell of Glasgow, Scotland. In the e-mail exchange a senior marketing manager for Pfizer and a professional medical writer discussed how to cast the results in a more favorable light for a poster presentation at a medical conference, the experts concluded.
“If Pfizer wants to use, present and publish this comparative data analysis in which two of the five studies compared make the overall picture look bad, how do we make it sound better than it looks on the graphs?” the medical writer asked.
Pfizer discontinued its marketing program for Neurontin in 2004 after the drug became available as a generic. That same year, the company paid $430 million to settle federal criminal and civil claims that Warner-Lambert, which Pfizer acquired in 2000, promoted Neurontin for unapproved uses during the 1990s.
At the time, Pfizer said the illegal marketing had occurred before Pfizer acquired the company or drug. On Tuesday, Pfizer repeated that it had instituted procedures when it acquired Warner-Lambert to make sure there was no off-label promotion of Neurontin.
Despite that settlement, separate legal action involving the drug is still pending in Boston, where consumers and third-party payers including insurance companies and trade unions want Pfizer to repay them billions of dollars for Neurontin prescriptions. The plaintiffs accuse Pfizer of fraudulently misrepresenting the drug’s benefits.
RollyInRaleigh
Legendary
The three letter agencies got their back...
Love this, thanks for posting.
At 1:20 mark, as he’s discussing Obama and the peaceful transfer of power, randomly in comes the military. Very cryptic, but seems to be a message of some sort. Could prove out to be a very powerful moment in our history.
Did they give the baby a Wuhan test before arrival and a Wuhan Jab as a condition of remaining in the hospital?
Done everything I know to do…that’s the only reason I am bringing it up here. I know we got some gurus on here. Hopefully you’re the good guys, and if not….come and get it.
They want bloodshed, give it to em.
Iran-Backed Militants Storm U.S. Embassy in Yemen, Seize Hostages and Equipment
The State Department is working to secure the release of several hostages taken by Iran-backed terrorists after they stormed the U.S. embassy facility in Sana'a, Yemen, U.S. officials told the Washington Free Beacon early Thursday.
freebeacon.com
Not sure how accurate, waiting for the President to confirm
